Short-term hormone therapy suspension and mammography recall: A randomized trial

Annals of Internal Medicine

Volumn 150, Issue 11, 2009, Pages 752-765

  Buist, Diana S M ^a,b   Anderson, Melissa L ^a,b   Reed, Susan D ^a,c   Aiello Bowles, Erin J ^a,b   Fitzgibbons, E Dawn ^a,b   Gandara, Juleann C ^a,d   Seger, Deborah ^a,b   Newton, Katherine M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Department of Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; AGED; ARTICLE; BREAST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE PLANNING; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSE; MONOTHERAPY; ORGAN SIZE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SHORT COURSE THERAPY; BREAST TUMOR; ESTROGEN THERAPY; FOLLOW UP; HISTOLOGY; MIDDLE AGED; PHYSIOLOGY; POSTMENOPAUSE; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; STANDARD; STATISTICS; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; WITHHOLDING TREATMENT;

EID: 66649086630     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-11-200906020-00003     Document Type: Article

References (58)

1. American Cancer Society. Cancer Facts & Figures 2008. Accessed at www.cancer.org/docroot/stt/content/stt-1x-cancer-facts-and-figures-2008.asp on 2 April 2009.
2. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347-360 [PMID: 12204020]
3. National Cancer Institute BCSC. Abnormal Interpretations for 4,032,556 Screening Mammography Examinations from 1996-2005. Accessed at breast-screening.cancer.gov/data/benchmarks/screening/table3.html on 6 April 2009.
4. Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol. 1995;165:1373-1377 [PMID: 7484568]
5. Barton MB, Moore S, Polk S, Shtatland E, Elmore JG, Fletcher SW. Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits. J Gen Intern Med. 2001;16:150-156 [PMID: 11318909] (Pubitemid 34208868)
6. Randal J. For breast cancer screening, there is room for improvement, report concludes. J Natl Cancer Inst. 2004;96:1200-1201 [PMID: 15316051] (Pubitemid 39232707)
7. Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168-175 [PMID: 12558355] (Pubitemid 36231622)
8. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst. 1992;84:781-785 [PMID: 1573665]
9. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000;92:1081-1087 [PMID: 10880551] (Pubitemid 30616482)
10. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995;87:1622-1629 [PMID: 7563205]
11. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology. 1995;196:433-437 [PMID: 7617857]
12. Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kelsey CA, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology. 1998;209:511-518 [PMID: 9807581] (Pubitemid 28503121)
13. Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst. 1996;88:643-649 [PMID: 8627640] (Pubitemid 26152550)
14. Buist DS, Aiello EJ, Miglioretti DL, White E. Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle. Cancer Epidemiol Biomarkers Prev. 2006;15:2303-2306 [PMID: 17119062] (Pubitemid 44877060)
15. White E, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter P, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst. 1998;90:906-910 [PMID: 9637139] (Pubitemid 28304158)
16. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomarkers Prev. 2001;10:141-142 [PMID: 11219771] (Pubitemid 32172433)
17. Baines CJ, Vidmar M, McKeown-Eyssen G, Tibshirani R. Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer. 1997;80:720-724 [PMID: 9264355] (Pubitemid 27339827)
18. Boudreau DM, Buist DS, Rutter CM, Fishman PA, Beverly KR, Taplin S. Impact of hormone therapy on false-positive recall and costs among women undergoing screening mammography. Med Care. 2006;44:62-69 [PMID: 16365614]
19. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001;285:171-176 [PMID: 11176809] (Pubitemid 32048518)
20. Harvey JA, Pinkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst. 1997;89:1623-1625 [PMID: 9362162] (Pubitemid 27479724)
21. Speroff L. The impact of the Women's Health Initiative on clinical practice [Editorial]. J Soc Gynecol Investig. 2002;9:251-253 [PMID: 12383908] (Pubitemid 35292293)
22. Burnside ES, Trentham-Dietz A, Kelcz F, Collins J. An example of breast cancer regression on imaging. Radiology Case Reports. 2006;1:27-37.
23. Institute of Medicine. Improving Breast Imaging Quality Standards. Washington, DC: National Academies Pr; 2005.
24. Smith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, et al. Comparison of screening mammography in the United States and the United kingdom. JAMA. 2003;290:2129-2137 [PMID: 14570948] (Pubitemid 37432973)
25. Elmore JG, Nakano CY, Koepsell TD, Desnick LM, D'Orsi CJ, Ransohoff DF. International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst. 2003;95:1384-1393 [PMID: 13130114] (Pubitemid 37220458)
26. Smith-Bindman R, Chu P, Miglioretti DL, Quale C, Rosenberg RD, Cutter G, et al. Physician predictors of mammographic accuracy. J Natl Cancer Inst. 2005;97:358-367 [PMID: 15741572] (Pubitemid 40425954)
27. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008;100:1082-1091 [PMID: 18664650]
28. Taplin SH, Thompson RS, Schnitzer F, Anderman C, Immanuel V. Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative. Cancer. 1990;66:812-818 [PMID: 2386908] (Pubitemid 20281331)
29. Taplin SH, Ichikawa L, Buist DS, Seger D, White E. Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev. 2004;13:225-234 [PMID: 14973097]
30. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). 3rd ed. Reston, VA: American Coll of Radiology; 1998.
31. Lee HP, Gourley L, Duffy SW, Estève J, Lee J, Day NE. Risk factors for breast cancer by age and menopausal status: a case-control study in Singapore. Cancer Causes Control. 1992;3:313-322 [PMID: 1617118]
32. Wiklund I, Holst J, Karlberg J, Mattsson LA, Samsioe G, Sandin K, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas. 1992;14:211-224 [PMID: 1508061]
33. Wiklund I, Karlberg J. Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Control Clin Trials. 1991;12:204S-216S. [PMID: 1663856]
34. Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004;104:1042-1050 [PMID: 15516400] (Pubitemid 40458772)
35. North American Menopause Society. Menopause Core Curriculum Study Guide. 2nd ed. Cleveland, OH: North American Menopause Soc; 2002.
36. A new conjugated estrogen. Med Lett Drugs Ther. 1999;41:67-68 [PMID: 10445019]
37. Taplin SH, Ichikawa L, Yood MU, Manos MM, Geiger AM, Weinmann S, et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst. 2004;96:1518-1527 [PMID: 15494602]
38. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. Automated analysis of mammographic densities. Phys Med Biol. 1996;41:909-923 [PMID: 8735257] (Pubitemid 26156945)
39. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Ehrlich K. Night sweats, sleep disturbance, and depression associated with diminished libido in late menopausal transition and early postmenopause: baseline data from the Herbal Alternatives for Menopause Trial (HALT). Am J Obstet Gynecol. 2007;196: 593.e1-7; discussion 593.e7. [PMID: 17547910] (Pubitemid 46836623)
40. Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, et al. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol. 2008;167:1027-1036 [PMID: 18385204]
41. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003;95:30-37 [PMID: 12509398] (Pubitemid 36124293)
42. Byrne C. Invited commentary: assessing breast density change-lessons for future studies. Am J Epidemiol. 2008;167:1037-1040 [PMID: 18385205]
43. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:1133-1144 [PMID: 9865433] (Pubitemid 29001671)
44. Marchesoni D, Driul L, Ianni A, Fabiani G, Della Martina M, Zuiani C, et al. Postmenopausal hormone therapy and mammographic breast density. Maturitas. 2006;53:59-64. [PMID: 15939560] (Pubitemid 41736060)
45. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Vlachou S, Creatsa M, Panoulis KP, et al. The effect of low dose hormone therapy on mammographic breast density. Maturitas. 2006;54:78-85. [PMID: 16198519]
46. Erel CT, Esen G, Seyisoglu H, Elter K, Uras C, Ertungealp E, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas. 2001;40:151-157 [PMID: 11716993] (Pubitemid 33079174)
47. Junkermann H, von Holst T, Lang E, Rakov V. Influence of different HRT regimens on mammographic density. Maturitas. 2005;50:105-110 [PMID: 15653007]
48. Lundström E, Wilczek B, von Palffy Z, Söderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999;181:348-352 [PMID: 10454681] (Pubitemid 29409912)
49. Harvey J, Scheurer C, Kawakami FT, Quebe-Fehling E, de Palacios PI, Ragavan VV. Hormone replacement therapy and breast density changes. Climacteric. 2005;8:185-192 [PMID: 16096175] (Pubitemid 40862995)
50. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999;13:829-836 [PMID: 10379882] (Pubitemid 30645301)
51. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11:1593-1607 [PMID: 9328342] (Pubitemid 27435408)
52. Beam CA, Guse CE, Sullivan DC. A sequential chart for the audit-based evaluation of screening mammogram interpretation. Acad Radiol. 1999;6:216-223 [PMID: 10894079] (Pubitemid 32667412)
53. Beam CA, Layde PM, Sullivan DC. Variability in the interpretation of screening mammograms by US radiologists. Findings from a national sample. Arch Intern Med. 1996;156:209-213 [PMID: 8546556]
54. Elmore JG, Wells CK, Lee CH, Howard DH, Feinstein AR. Variability in radiologists' interpretations of mammograms. N Engl J Med. 1994;331:1493-1499 [PMID: 7969300] (Pubitemid 24356309)
55. Kerlikowske K, Grady D, Barclay J, Frankel SD, Ominsky SH, Sickles EA, et al. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System. J Natl Cancer Inst. 1998;90:1801-1809 [PMID: 9839520] (Pubitemid 28559892)
56. Taplin SH, Rutter CM, Lehman CD. Testing the effect of computerassisted detection on interpretive performance in screening mammography. AJR Am J Roentgenol. 2006;187:1475-1482 [PMID: 17114540] (Pubitemid 44788677)
57. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338:1089-1096 [PMID: 9545356] (Pubitemid 28227478)
58. Centers for Medicare & Medicaid Services. In the Medicare population in the year 2005, 11.4 million non-HMO women between the ages of 50 to 79 years of age received a reimbursed screening mammogram. Vol.2008. Baltimore: Centers for Medicare & Medicaid Services; 2005.